Contempo Updates | Clinician's Corner

New Avenues of Exploration for Erythropoietin

Kenneth Maiese, MD; Faqi Li, MD, PhD; Zhao Zhong Chong, MD, PhD
JAMA. 2005;293(1):90-95. doi:10.1001/jama.293.1.90.
Text Size: A A A
Published online

Discovery that the hormone erythropoietin (EPO) and its receptor play a significant biological role in tissues outside of the hematopoietic system has fueled significant interest in EPO as a novel cytoprotective agent in both neuronal and vascular systems. Erythropoietin is now considered to have applicability in a variety of disorders that include cerebral ischemia, myocardial infarction, and chronic congestive heart failure. Erythropoietin modulates a broad array of cellular processes that include progenitor stem cell development, cellular integrity, and angiogenesis. As a result, cellular protection by EPO is robust and EPO inhibits the apoptotic mechanisms of injury, including the preservation of cellular membrane asymmetry to prevent inflammation. As the investigation into clinical applications for EPO that maximize efficacy and minimize toxicity progresses, a deeper appreciation for the novel roles that EPO plays in the brain and heart and throughout the entire body should be acquired.

Figures in this Article


Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours


Figure. Potential Mechanism of Erythropoietin Cytoprotection
Graphic Jump Location

Erythropoietin (EPO) and the EPO receptor (EPOR) prevent apoptosis and cellular inflammation through a series of pathways that originate with the binding of EPO to the EPOR to activate Janus-tyrosine kinase 2 (Jak2), phosphoinositide 3 kinase (PI 3-K), and protein kinase B (Akt). The signal transducer and activator or transcription (STAT) proteins are direct substrates of Jak2. Activation of the specific gene product STAT5 can regulate EPO mediated cell proliferation and protect against apoptosis. Downstream from activation of Jak2 and Akt, EPO modulates phosphorylation of the fork head family member FOXO3a, glycogen synthase kinase-3β (GSK-3β), and nuclear factor-κB (NF-κB). Hypoxia increases the expression of hypoxia-inducible factor-1 (HIF-1) resulting in the direct enhancement of EPO expression and a hypoxic-driven increase in EPOR expression. Erythropoietin maintains cellular integrity and prevents apoptosis through a number of pathways, such as those involving Bcl-xL (for the maintenance of mitochondrial membrane potential), the modulation of apoptosis protease activating factor (Apaf)-1, the release of cytochrome C, and the activation of caspases 1, 3, and 9. Erythropoietin also modulates cellular inflammation by inhibiting cellular phosphatidylserine membrane exposure and the subsequent targeting of cells for phagocytosis.




You need to register in order to view this quiz.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 317

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.